Tag Archives: Acute

FDA Approves Rylaze for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

FDA Approves Rylaze for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma DUBLIN, June 30, 2021 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute… Read More »

Diagnosing Acute Compartment Syndrome: Interview with Charles Allan, CEO of MY01

MY01, a medtech company based in Montreal, has developed the Continuous Compartment Pressure Monitor, a sterile, single-use device for the diagnosis of acute compartment syndrome. If undiagnosed and untreated, acute compartment syndrome, a condition caused by high pressure around muscles typically following an injury, can have significant consequences for patients. Long-term disability and amputation is… Read More »

Sprycel (dasatinib) Tablets Now Approved in Combination with Chemotherapy in Certain Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Print this page PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel ® (dasatinib) tablets to include the treatment of pediatric patients one year of age and older with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in combination with chemotherapy.1 Sprycel… Read More »

Severe Rhabdomyolysis in a Patient With Acute Influenza Infection

January 03, 2019 This article originally appeared here. Share this content: Rhabdomyolysis is characterized by breakdown of muscle tissue A recently published case report describes the case of a 29-year-old male patient with influenza-induced rhabdomyolysis and highlights the need to assess creatinine kinase (CK) levels of patients hospitalized with influenza. The patient, who had a… Read More »

FDA Approves Daurismo (glasdegib) for Patients with Acute Myeloid Leukemia

FDA Approves Daurismo (glasdegib) for Patients with Acute Myeloid Leukemia Print this page November 21, 2018 — The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75… Read More »

Which Drug Combination Works Best to Reduce Acute COPD Exacerbations?

November 20, 2018 Share this content: A higher blood eosinophil count was associated with a greater protective effect of ICS/LABA/LAMA against severe acute COPD exacerbations. A combination of inhaled corticosteroids (ICS)/long-acting β2-agonist (LABA)/long-acting muscarinic receptor antagonist (LAMA) is possibly more effective than a LABA/LAMA combination or single long-acting bronchodilator therapy in reducing the risk for… Read More »